Basic Information on the Pharmaceutical Industry

Overview of Domestic Pharmaceutical Market and NHI Drug Prices

Trends in National Medical Expenses

Without medical system reforms, Japan’s national medical expenses will increase at an annual rate of approximately 2 to 4 percent going forward. In fiscal 2018 (the year ended March 2019), national medical expenses totaled ¥42.6 trillion, a ¥0.4 trillion or 0.8 percent increase from the previous year. The government reduced reimbursement prices by 0.93 percent on a government spending basis (+0.42 percent to reflect the consumption tax increase in October 2019). In its fiscal 2019 budget, the Japanese government decided to reduce reimbursement prices in conjunction with the consumption tax increase in October 2019. In its fiscal 2019 budget, the Japanese government government reduced reimbursement prices by 0.51 percent on a government spending basis (+0.42 percent to reflect the consumption tax and -0.93 percent revision based on actual market prices and other factors).

A special revision of drug reimbursement prices was implemented in conjunction with the consumption tax increase in October 2019. In its fiscal 2019 budget, the Japanese government government reduced reimbursement prices by 0.51 percent on a government spending basis (+0.42 percent to reflect the consumption tax and -0.93 percent revision based on actual market prices and other factors).

Promotion of the Use of Generics

The Japanese government is promoting the use of generics with the primary objective of reducing the cost burden on patients and improving the finances of the health insurance system. Various measures have been carried out under the action program announced in October 2007 to promote the worry-free use of generics. In April 2013, the new “Roadmap to Further Promote the Use of Generics” was formulated. A Cabinet decision in June 2017 set the new goal of raising the volume market share of generics, which was 76.7 percent2 as of September 2019, to 80 percent by the end of September 2020. The government is also aiming to double the number of biosimilars by the end of 2020. The government is also aiming to double the number of biosimilars by the end of 2020.

National Health Insurance (NHI) Drug Price Revision

The Ministry of Health, Labour and Welfare (MHLW) generally reviews drug reimbursement prices every two years and sets new standard prices (reimbursement prices) so that the official prices of pharmaceuticals prescribed under the health insurance system approximate their actual market price. MHLW does this by investigating the prices and volumes of all prescription drug transactions during a given period.

A special revision of drug reimbursement prices was implemented in conjunction with the consumption tax increase in October 2019. In its fiscal 2019 budget, the Japanese government reduced reimbursement prices by 0.51 percent on a government spending basis (+0.42 percent to reflect the consumption tax and -0.93 percent revision based on actual market prices and other factors).

Repricing Based on Market Expansion

Under this repricing rule introduced in 1994, drugs priced by the cost calculation method with annual sales exceeding ¥10.0 billion and more than 10 times the original forecast at the time of price revision, or with annual sales exceeding ¥15.0 billion and more than two times the original forecast, are subject to a price reduction of up to 25.0 percent.
Drugs priced by methods other than the cost calculation method (including the similar efficacy comparison method) with annual sales exceeding ¥15.0 billion and more than two times the original forecast at the time of the price revision are subject to a price reduction of up to 15.0 percent. In addition, the prices of drugs that have pharmacological action similar to a drug subject to this repricing rule are reduced by the same rate. In the NHI drug pricing system fundamental reforms of fiscal 2018, it was decided to use the NHI listing of new drugs that takes place four times a year as an opportunity for repricing of drugs with annual sales exceeding ¥35.0 billion. The purpose of this change is to respond more quickly when sales expand rapidly due to an additional indication or other reasons.

Special Market-Expansion Repricing
In the reforms to the drug pricing system in fiscal 2016, an additional repricing rule for drugs with very high annual sales was introduced as a special measure from the standpoint of balancing reward for innovation with the sustainability of the National Health Insurance system. This rule lowers prices by up to 25.0 percent for drugs with annual sales of ¥100.0–150.0 billion and more than 1.5 times the original forecast, and lowers prices by up to 50.0 percent for drugs with annual sales exceeding ¥150.0 billion and more than 1.3 times the original forecast. In addition, the prices of drugs that have pharmacological action similar to a drug subject to the special repricing rule and were comparator drugs at the time of the NHI price listing are reduced by the same rate. In the NHI drug pricing system fundamental reforms of fiscal 2018, it was decided to use the NHI listing of new drugs that takes place four times a year as an opportunity for repricing under this scheme.

Premium to Promote the Development of New Drugs and Eliminate Off-Label Use
As part of the NHI drug pricing system reforms of fiscal 2010 (the year ended March 2011), a new pricing scheme was implemented on a trial basis to promote the creation of innovative medical products and solve the drug lag problem. In this scheme, at the time of the NHI drug price revisions, prices are maintained on drugs for which no generics are available (provided that they have been in the NHI price list for no more than 15 years), and which satisfy certain conditions.

This premium pricing for new drugs was continued on a trial basis in subsequent NHI drug pricing system reforms. However, in the NHI drug pricing system fundamental reforms of fiscal 2018, the decision was made to revise the requirements for companies and products and list them in the drug repricing rules.

Companies that do not respond appropriately to development requests from MHLW will continue to be excluded from eligibility for premium pricing. In addition, indicators have been set for (A) creation of innovative drugs and treatments for antimicrobial-resistant bacteria, (B) drug lag countermeasures, and (C) development of novel drugs ahead of other

### Response to Requests from the MHLW Review Committee on Unapproved Drugs and Indications with High Medical Needs
(As of January 30, 2020)

<table>
<thead>
<tr>
<th>Development request</th>
<th>Product</th>
<th>Indication</th>
<th>Development status</th>
</tr>
</thead>
<tbody>
<tr>
<td>First development request</td>
<td>Xeloda</td>
<td>Advanced or recurrent gastric cancer</td>
<td>Approved in February 2011</td>
</tr>
<tr>
<td></td>
<td>Tamova</td>
<td>Advanced or recurrent pancreatic cancer</td>
<td>Approved in July 2011</td>
</tr>
<tr>
<td></td>
<td>Avastin</td>
<td>Advanced or recurrent breast cancer</td>
<td>Approved in September 2011</td>
</tr>
<tr>
<td></td>
<td>CellCept</td>
<td>Pediatric renal transplant</td>
<td>Approved in September 2011</td>
</tr>
<tr>
<td></td>
<td>Herceptin</td>
<td>Q3W dosage metastatic breast cancer overexpressing HER2</td>
<td>Approved in November 2011</td>
</tr>
<tr>
<td></td>
<td>Kytril</td>
<td>Gastrointestinal symptoms associated with radiotherapy</td>
<td>Approved in December 2011</td>
</tr>
<tr>
<td></td>
<td>Pulmozyme</td>
<td>Improvement of pulmonary function in patients with cystic fibrosis</td>
<td>Approved in March 2012</td>
</tr>
<tr>
<td></td>
<td>Bactrim</td>
<td>Treatment and prevention of pneumocystis pneumonia</td>
<td>Approved in August 2012</td>
</tr>
<tr>
<td></td>
<td>Avastin</td>
<td>Ovarian cancer</td>
<td>Approved in November 2013</td>
</tr>
<tr>
<td></td>
<td>Avastin</td>
<td>Recurrent glioblastoma</td>
<td>Approved in June 2013 (Malignant glioma)</td>
</tr>
<tr>
<td></td>
<td>Herceptin</td>
<td>Q1W dosage postoperative adjuvant breast cancer overexpressing HER2</td>
<td>Approved in June 2013</td>
</tr>
<tr>
<td></td>
<td>CellCept</td>
<td>Lupus nephritis</td>
<td>Approved in May 2016</td>
</tr>
<tr>
<td>Second development request</td>
<td>Tamiflu</td>
<td>Additional dosage for neonates and infants younger than 12 months</td>
<td>Approved in March 2017</td>
</tr>
<tr>
<td></td>
<td>Xeloda</td>
<td>Adjuvant chemotherapy in rectal cancer</td>
<td>Approved in August 2016</td>
</tr>
<tr>
<td></td>
<td>Avastin</td>
<td>Additional Q2W dosage and administration for ovarian cancer</td>
<td>Submitted company opinion and waiting for evaluation by committee</td>
</tr>
<tr>
<td></td>
<td>Copegus</td>
<td>Improvement of viraemia associated with genotype 3 chronic hepatitis C or compensated cirrhosis related to hepatitis C when administered in combination with sofosbuvir</td>
<td>Approved in March 2017</td>
</tr>
<tr>
<td></td>
<td>Xeloda</td>
<td>Neuroendocrine tumor</td>
<td>Submitted company opinion and waiting for evaluation by committee</td>
</tr>
<tr>
<td></td>
<td>Avastin</td>
<td>Cerebral edema induced by radiation necrosis</td>
<td>Submitted company opinion and waiting for evaluation by committee</td>
</tr>
<tr>
<td></td>
<td>Neurontin</td>
<td>Combination therapy with chemotherapy including fludarabine for relapsed/refractory acute myeloid leukemia</td>
<td>Submitted company opinion and waiting for evaluation by committee</td>
</tr>
<tr>
<td></td>
<td>CellCept</td>
<td>Prevention of graft-versus-host disease in hematopoietic stem cell transplantation</td>
<td>Submitted company opinion and waiting for evaluation by committee</td>
</tr>
</tbody>
</table>
countries, and the pricing premiums may vary according to the level of achievement or fulfillment of these indicators. Healthcare related ventures are expected to play an important role in the creation of innovative drugs, and will be evaluated accordingly, irrespective of the company indicators.

Regarding the product requirements, the percentage price difference requirement will be abolished, and the price premium will be limited to novel drugs during their patent period, and drugs that are truly innovative and useful. More specifically, it will be limited to orphan drugs; drugs for which development was publicly requested; drugs to which the premium was applied because of their usefulness, such as at the time they were newly listed; drugs with novel mechanisms of action that are innovative or useful (limited to the top three first-in-class drugs within three years from listing) or that have newly added efficacy or effectiveness deemed equivalent to novel modes of action; drugs that have Sakigake designation; and treatments for antimicrobial-resistant bacteria.

Among new drugs subject to premium pricing, including those for which generics (including biosimilars) have been launched or 15 years have elapsed since their drug price listing, the cumulative amount of premium pricing is deducted from the NHI drug price in the subsequent initial drug price revision. Furthermore, a reduction or other adjustment due to the actual market price of the new drug during the fiscal year is made to the NHI drug price less the cumulative amount.

3. The inability of Japanese patients to gain access to global standard or most advanced treatments because the drugs are not developed in Japan

Solving the Drug Lag Problem

In January 2005, MHLW established the Investigational Committee for Usage of Unapproved Drugs as one means of helping solve the drug lag problem. The committee is charged with investigating the clinical necessity and the appropriateness of usage of drugs already approved in Europe and the United States, but not yet approved in Japan. The aim of these investigations is to promote the development of those drugs in Japan. In February 2010, MHLW established the Review Committee on Unapproved Drugs and Indications with High Medical Needs. This committee evaluates the medical necessity of drugs and indications that are not yet approved in Japan and investigates matters such as the applicability of filings for approval based on evidence in the public domain. As a result of continuous efforts to strengthen the review function of the Pharmaceutical and Medical Devices Agency, an independent administrative institution responsible for reviewing drugs and medical devices for approval, the median total review time for new drugs in fiscal 2018 was 11.9 months. For new drug applications filed in Japan during fiscal 2018, the median review time was 0.2 years longer than that of the United States, but shorter than the average year lag.

Annual Drug Price Survey and Annual NHI Drug Price Revision

Due to the growing public financial burden of the current situation, in which drug prices are maintained for up to two years even if the market price declines, it was decided in the NHI drug pricing system fundamental reforms of fiscal 2018 that drug price surveys and drug price revisions will be carried out even in interim years when there would ordinarily be no price revisions. Fiscal 2018 and fiscal 2020 (the year ending March 2021) are price revision years even under the current system, and it is expected that a price revision will be implemented in conjunction with the consumption tax rate increase in October 2019. Therefore, the interim-year price revisions under the new rules will take place starting from fiscal 2021 (the year ending March 2022). The scope of items subject to interim-year price revisions will be deliberated by the Central Social Insurance Medical Council (Chuikyo) and other organizations.

Creation of a System for Cost-Effectiveness Assessments

A system of price adjustments based on cost-effectiveness assessments has been approved by Chuikyo, and was implemented in April 2019. The system primarily applies to products that meet the requirements of the selection criteria at the time of their NHI price listing. Cost-effectiveness assessments will be conducted for a certain period after the listing, and the price will be adjusted according to the results. The extent of the price adjustment is the portion corresponding to the amount of the corrective premium for usefulness applied at the time of the drug’s initial pricing (for products with a degree of disclosure under 50 percent, as calculated by the cost calculation method, the portion corresponding to operating profit is also subject to adjustment). Price adjustments will be made according to the incremental cost effectiveness ratio (ICER). The corrective premium will be maintained if the ICER is less than ¥5 million (less than ¥7.5 million for anticancer agents), but will be reduced in stages by up to 90 percent if the ICER is ¥5 million or more. The price adjustment will be limited to 10-15 percent of the total drug price.

The ICER indicates the extent to which additional investment would be necessary to obtain the additional benefit from replacing existing drug (technology) B with new drug A.
Leading Cause of Death in Japan

Cancer has been the single most common cause of death in Japan since 1981. In 2018, 373,584 people died of cancer, accounting for 27.4 percent of all deaths in that year and the highest number since government surveys began in 1899.

Establishment of the Basic Act for Anticancer Measures and Improvement in the Healthcare Environment

The Cancer Control Act was enacted in June 2006 to establish a system so that patients can receive appropriate treatment based on scientific knowledge regardless of the region in which they reside and with respect paid to their wishes, as well as to implement the Basic Plan to Promote Cancer Control Programs (the “Basic Plan”). Since the enactment of the Cancer Control Act, some results have been obtained, including establishment of designated cancer hospitals and a reduction of the cancer mortality rate and improvement of the five year survival rate owing to advances in cancer treatment. The goal of reducing the age-adjusted cancer mortality rate by 20 percent over the 10-year period from fiscal 2007 was judged difficult to achieve, and therefore, in December 2015, the Plan for Acceleration of Cancer Control Programs was formulated. This plan specified concrete measures that should be implemented intensively in a short period of time.

In recent years, it has become apparent that new measures are necessary to fight rare cancers, difficult-to-treat cancers, childhood cancers, and cancers in adolescents and young adults (AYA); to promote new treatments such as genomic medicine; and to address societal problems including employment. The principles of the Cancer Control Act stipulate that the national and local governments make effective use of healthcare and welfare resources and implement cancer control measures from the viewpoint of serving the public in order to achieve the stated goal of creating a society in which cancer patients can live with peace of mind and dignity. In the 3rd Basic Plan to Promote Cancer Control Programs released in March 2018, measures are being implemented to educate the public, including patients, about cancer and help them to overcome it. These measures are based on four pillars – cancer prevention, improvement of cancer care, living with cancer and deployment of infrastructure to support those measures.

Changes in Treatment Methods

Cancer treatment is increasingly being based on a multidisciplinary approach that combines surgery, radiation therapy and drug therapy. In particular, the field of anticancer agents is evolving, and highly innovative medicines such as molecular targeted drugs have been introduced. This has brought dramatic improvement in treatment outcomes for various types of cancer.

Advances are being made in personalized healthcare (PHC), which involves testing patients with companion diagnostics when administering molecular targeted drugs to identify patients who are likely to benefit with minimal strain on the body and few side effects. In addition to enabling physicians to propose the optimal treatment tailored to each patient, this approach offers a number of other benefits. For example, it can reduce national healthcare expenditures by reducing the administration of drugs when their effect cannot be determined.

Diagnosis with comprehensive genomic profiling (CGP), such as genomic testing using next-generation sequencing, is also becoming important. In improvement of cancer care, one of the pillars of the above-mentioned Basic Plan, cancer genomic medicine heads the list of measures, and practical application of CGP testing was promoted as an important government-led initiative. As a result, in June 2019 CGP, which entails comprehensive analysis and profiling of genes in a single test using solid tumor tissue from the patient, became eligible for health insurance coverage. The provision of optimal treatments based on each patient’s genomic profile has thus become a reality. Genomic medicine started in the oncology field, but is now being promoted for intractable diseases and other diseases, in line with the “Action Plan of the Growth Strategy,” “Follow-up on the Growth Strategy” and “Action Plan for Innovative Business Activities” in FY 2019, which were approved by the Cabinet in June 2019. This is expected to further advance precision medicine in ways such as promoting the development of treatment approaches that utilize genomic information obtained not only through genomic analysis of cancer tissue, but through entire genome analysis.

Cancer immunotherapy, which takes advantage of the body’s own immune cells to fight cancer, is another important emerging field of treatment. Immune checkpoint inhibitors, one type of immunotherapy now in use, are a promising new direction in cancer treatment. Cancer has the ability to suppress (apply brakes to) immune functions to avoid attack from the immune system, but immune checkpoint inhibitors block the immune “brakes” (the binding of PD-1 to PD-L1) known as the immune checkpoint, thereby awakening immune cells to attack cancer cells. In clinical study results, immune checkpoint inhibitors have shown promise for long-term survival and cure, even in advanced cancer. Their high therapeutic efficacy is also recognized in clinical settings, and they are increasingly used as treatments for a wide range of cancers. However, some patients do not respond to cancer immunotherapy, so screening to select patients for whom this therapy is likely to be effective is also being examined, as are various combinations with existing anticancer agents and development candidates, and development for use in early-stage cancer.

FoundationOne CDx Cancer Genomic Profile

Basic Information

FoundationOne CDx Cancer Genomic Profile (F1CDx), developed by U.S.-based Foundation Medicine, Inc., is a next-generation sequencing-based diagnostic device. It detects substitutions, insertion and deletion alterations, and copy number alterations in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability.
including breast cancer, has increased the use of Avastin for other indications, and other products. On the other hand, introduction of immune checkpoint inhibitors competitive environment in the field of colorectal cancer and lung cancer, but the previous year at ¥95.6 billion. Avastin has Sales of Avastin were unchanged from the Review of 2019 Performance May 2016.

Advanced or recurrent cervical cancer in glioma and ovarian cancer in 2013, and for the additional indications of malignant breast cancer. Chugai also obtained approval followed in 2011 by inoperable or recurrent squamous unresectable advanced or recurrent non-cancer and the additional indication of malignant breast cancer. Since its launch in 2001.

Avastin is a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF). It is the first therapeutic agent in the world that inhibits angiogenesis (the growth of the network of blood vessels that supply nutrients and oxygen to the cancer). Unlike conventional anticancer agents that act directly on cancer cells, Avastin acts on the cancer microenvironment. In Japan, Avastin was launched in 2007 for the treatment of unresectable advanced or recurrent colorectal cancer. In 2009, Chugai obtained approval for a new dosage and administration for colorectal cancer and the additional indication of unresectable advanced or recurrent non-squamous non-small cell lung cancer (NSCLC), followed in 2011 by inoperable or recurrent breast cancer. Chugai also obtained approval for the additional indications of malignant glioma and ovarian cancer in 2013, and advanced or recurrent cervical cancer in May 2016.

Review of 2019 Performance Sales of Avastin were unchanged from the previous year at ¥95.6 billion. Avastin has built a solid position in the treatment of colorectal cancer and lung cancer, but the competitive environment in the field of lung cancer has been changing due to the introduction of immune checkpoint inhibitors and other products. On the other hand, the use of Avastin for other indications, including breast cancer, has increased steadily. Global phase III studies in combination with Tencetrix in renal cell carcinoma and hepatocellular carcinoma patients are under way.

In February 2020, we filed applications for the combination of Tencetrix and Avastin for the treatment of unresectable hepatocellular carcinoma.

**Avastin (RG435)**

Anti-VEGF humanized monoclonal antibody (Generic name: bevacizumab) Launch in Japan: June 2007

**Basic Information**

Avastin is a humanized monoclonal antibody that targets human epidermal growth factor receptor type 2 (HER2), which contributes to tumor cell growth. The earliest PHC-based anticancer agent, Herceptin has built a solid reputation as an essential treatment for HER2-positive breast cancer since its launch in 2001.

Overexpression of HER2 is found in about 20 percent of breast cancers. Such cancer is diagnosed as HER2-positive. HER2-positive breast cancer progresses rapidly, and has been associated with a poor prognosis. However, treatment outcomes have improved significantly with the emergence of Herceptin and other medicines that target HER2. In 2011, Herceptin obtained approval for the additional indication of advanced or recurrent gastric cancer overexpressing HER2, not amenable to curative resection, bringing PHC to the field of gastric cancer.

**Review of 2019 Performance**

Sales of Herceptin decreased ¥1.4 billion, or 5.0 percent, year on year to ¥26.7 billion. The decrease reflected the substantial NHJ drug price revision (-20.4 percent) that resulted from the exclusion from eligibility for the premium for new drug creation.

**Anticancer Agent Market in Japan**

(Billions of yen)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Monoclonal antibodies</td>
<td>¥95.6</td>
<td>¥85.7</td>
<td>¥85.9</td>
<td>¥85.6</td>
<td>¥72.5</td>
<td>¥70.5</td>
<td>¥70.3</td>
<td>¥70.1</td>
<td>¥69.8</td>
<td>¥70.1</td>
</tr>
<tr>
<td>Hormone therapy</td>
<td>¥1.5</td>
<td>¥1.7</td>
<td>¥1.8</td>
<td>¥1.6</td>
<td>¥1.7</td>
<td>¥1.7</td>
<td>¥1.7</td>
<td>¥1.8</td>
<td>¥1.9</td>
<td>¥2.0</td>
</tr>
<tr>
<td>Antimetabolites</td>
<td>¥2.0</td>
<td>¥2.2</td>
<td>¥2.3</td>
<td>¥2.4</td>
<td>¥2.5</td>
<td>¥2.6</td>
<td>¥2.7</td>
<td>¥2.8</td>
<td>¥2.9</td>
<td>¥3.0</td>
</tr>
<tr>
<td>Bisphosphonates</td>
<td>¥0.5</td>
<td>¥0.6</td>
<td>¥0.7</td>
<td>¥0.8</td>
<td>¥0.9</td>
<td>¥1.0</td>
<td>¥1.1</td>
<td>¥1.2</td>
<td>¥1.3</td>
<td>¥1.4</td>
</tr>
<tr>
<td>Others</td>
<td>¥0.5</td>
<td>¥0.6</td>
<td>¥0.7</td>
<td>¥0.8</td>
<td>¥0.9</td>
<td>¥1.0</td>
<td>¥1.1</td>
<td>¥1.2</td>
<td>¥1.3</td>
<td>¥1.4</td>
</tr>
</tbody>
</table>

Widely used in first-line treatment of HER2-positive advanced or recurrent breast cancer in combination with Perjeta, Herceptin is also used for more than 90 percent of lymph-node positive patients undergoing postoperative (adjuvant) therapy for HER2-positive early breast cancer. Since October 2018, it has been widely used in combination with Perjeta, after Perjeta became available as a neoadjuvant and adjuvant therapy in early breast cancer. For gastric cancer, although Herceptin maintained its established position in first-line treatment, sales decreased slightly due to competition in second-line treatment.

1. A diagnostic test can determine if a patient’s breast or gastric cancer cells have overexpression of a protein called HER2. Herceptin, Perjeta and Kadcyla target HER2 and are administered only to patients whose tumors are identified as HER2-positive.

**Herceptin (RG1273)**

HER2 dimerization inhibitory humanized monoclonal antibody (Generic name: pertuzumab) Launch in Japan: September 2013

**Basic Information**

Perjeta is a humanized monoclonal antibody and is the first molecular targeted therapy that inhibits the dimerization of HER2. The combination of Perjeta and Herceptin, which also targets HER2, provides a more comprehensive blockade of HER signaling pathways associated with the proliferation of tumor cells. Chugai launched Perjeta for the indication of HER2-positive inoperable or recurrent breast cancer in September 2013, after obtaining approval in June 2013. In 2018, Perjeta obtained approval for the additional indication of neoadjuvant and adjuvant therapy for HER2-positive breast cancer.

**Review of 2019 Performance**

Sales of Perjeta increased ¥14.6 billion, or 90.7 percent, year on year to ¥29.7 billion, exceeding projections by a wide margin. The combination of Herceptin and Perjeta with a chemotherapy agent for neoadjuvant and adjuvant for HER2-positive early breast cancer, an additional indication approved in October 2018, penetrated the market faster than expected. In addition, a global phase III study is under way for RG6264 (subcutaneous injection), a fixed-dose combination of Herceptin and Perjeta, for HER2-positive breast cancer.

**Kadcyla (RG3502)**

Anti-HER2 antibody-tubulin polymerization inhibitor conjugate (Generic name: trastuzumab emtansine) Launch in Japan: April 2014

**Basic Information**

Kadcyla is an antibody-drug conjugate of the anti-HER2 humanized monoclonal antibody trastuzumab (product name: Herceptin) and...
Extensive Contribution to Cancer Treatment (Breast Cancer)

Immune checkpoint inhibitor
Tecentriq

Antimetabolites
Xeloda

Treatment of breast cancer
Early breast cancer
Neoadjuvant
Operation
Adjuvant

Advanced/relapsed breast cancer
Hormone therapy
Chemotherapy

Supportive care
Neutrogin

Molecular targeting therapy
Herceptin
Perjeta
Kadcyla
Avastin
Review of 2019 Performance

Sales of Tecentriq increased ¥11.5 billion, or 126.4 percent, year on year to ¥20.6 billion, substantially higher than expected. Sales increased because in its position in second-line treatment and beyond for NSCLC, it can be prescribed regardless of PD-L1 expression, and because of steady uptake in combination with Avastin and chemotherapy in first-line treatment of unresectable, advanced or recurrent NSCLC.

Gazyva (GA101)

Glycoengineered type II anti-CD20 monoclonal antibody
(Generic name: obinutuzumab)
Launch in Japan: August 2018

Basic Information
Gazyva is a glycoengineered type II monoclonal antibody in-licensed from Roche that, like Rituxan, targets CD20. A study that directly compared its efficacy and safety with Rituxan, currently the most widely used monoclonal antibody, in patients in Japan and overseas (the GALLIUM study) was terminated early for benefit after positive results were reported. Gazyva obtained approval for the treatment of CD20-positive follicular lymphoma in July 2018, and was launched in August 2018.

In November 2012, Chugai entered into an agreement with Nippon Shinyaku Co., Ltd. to co-develop and co-market this agent in Japan.

Review of 2019 Performance

Sales of Gazyva, which was launched in August 2018, increased ¥3.0 billion, or 500.0 percent, year on year to ¥3.6 billion. Steady sales growth was driven by uptake in Rituxan-naïve or recurrent patients.

Rozlytrek (RG6268)

ROS1/TRK inhibitor
(Generic name: entrectinib)
Launch in Japan: September 2019

Basic Information
Rozlytrek, in-licensed from Roche, is an orally bioavailable CNS-active tyrosine kinase inhibitor that potently and selectively inhibits ROS1 and the TRK family, and also acts on brain metastases. Targeting NTRK fusion gene-positive solid tumors, RG6268 has been granted breakthrough therapy designation in the United States, PRIorityMEdicines (PRIIME) designation in the EU, and Sakigake designation in Japan. Chugai obtained the world’s first approval for the treatment of NTRK fusion gene-positive advanced/recurrent solid tumors in Japan in June 2019, and launched the product in September 2019.

Rozlytrek is a tumor-agnostic therapy that uses a next-generation sequencing-based companion diagnostic to identify target genomic alterations that drive cancer, thus embodying the advanced PHC that Chugai is promoting. F1CDx obtained approval in June 2019.

Basic Information
Rozlytrek, in-licensed from Roche, is an orally bioavailable CNS-active tyrosine kinase inhibitor that potently and selectively inhibits ROS1 and the TRK family, and also acts on brain metastases. Targeting NTRK fusion gene-positive solid tumors, RG6268 has been granted breakthrough therapy designation in the United States, PRIorityMEdicines (PRIIME) designation in the EU, and Sakigake designation in Japan. Chugai obtained the world’s first approval for the treatment of NTRK fusion gene-positive advanced/recurrent solid tumors in Japan in June 2019, and launched the product in September 2019.

Rozlytrek is a tumor-agnostic therapy that uses a next-generation sequencing-based companion diagnostic to identify target genomic alterations that drive cancer, thus embodying the advanced PHC that Chugai is promoting. F1CDx obtained approval in June 2019.
2019 as a companion diagnostic for Rozlytrek. Chugai obtained approval for ROS1 unresectable, advanced, or recurrent fusion gene-positive NSCLC in February 2020.

**GC33 (RG7686) Development project**
Anti-glypican-3 humanized monoclonal antibody
(Generic name: codrituzumab)

GC33, a humanized monoclonal antibody created by Chugai, targets glypican-3 (GPC3), which is specifically expressed in hepatocellular carcinoma. GC33 did not meet the primary endpoint in a global phase II monotherapy study started in March 2012. A phase I clinical study for hepatocellular carcinoma in combination with Tecentriq has been under way since August 2016, and the study results were presented at the European Society of Medical Oncology (ESMO) 2018 Congress.

**ERY974 Development project**
Anti-glypican-3/CD3 bispecific antibody

ERY974 is the first T-cell redirecting antibody (TRAB) developed by Chugai. TRAB is a bispecific antibody that creates a short bridge between CD3 on T cells and tumor antigen on tumor cells to activate T cells in a tumor antigen-dependent manner, and is expected to demonstrate strong cytotoxicity against tumor cells. GPC3, a tumor antigen targeted by ERY974, is reported to be expressed in multiple types of tumor cells including hepatocellular carcinoma, lung cancer, gastric cancer and esophageal cancer. A phase I clinical trial is under way.

**RG7596 Development project**
Anti-CD79b antibody-drug conjugate
(Generic name: polatuzumab vedotin)

RG7596 is an antibody-drug conjugate of an anti-CD79b monoclonal antibody and the microtubule inhibitor MMAE, joined together with a linker. In-licensed from Roche, the conjugate is designed to deliver MMAE directly into B cells via CD79b, which is expressed on B cells, so that the inhibitor can act. To demonstrate a cytostatic effect on tumor cells, a global phase III study for previously untreated diffuse large B-cell lymphoma (DLBCL) started in November 2017. In addition, a phase II clinical study for relapsed or refractory DLBCL started in Japan in October 2018 and achieved a primary endpoint in February 2020. In November 2019, RG7596 received MHLW orphan drug designation for the treatment of DLBCL.

**RG7440 Development project**
AKT inhibitor
(Generic name: ipatasertib)

RG7440 is an AKT inhibitor in-licensed from Roche. Global phase III studies started in June 2017 for prostate cancer and in January 2018 for breast cancer. For breast cancer, a new of global phase III studies are either beginning or in preparation with the aim of adding further indications.

**RG7421 Development project**
MEK inhibitor
(Generic name: cobimetinib fumarate)

RG7421 is an MEK inhibitor in-licensed from Roche. Chugai started a phase I clinical study for the treatment of solid tumors in Japan in July 2017.

**RG7802 Development project**
Anti-CEA/CD3 bispecific antibody
(Generic name: cibisatamab)

RG7802, a bispecific antibody in-licensed from Roche, is expected to activate T-cells and attack tumor cells by cross-linking CD3 on T-cells to carcinoembryonic antigen (CEA) on tumor cells. With a novel structure engineered to bind simultaneously with one arm to CD3 on T-cells and two arms to CEA on tumor cells, it exhibits higher tumor selectivity and stronger binding to CEA. CEA is reported to be overexpressed in a variety of cancers, including colorectal cancer.

RG7802-mediated intra-tumor T-cell proliferation may yield efficacy in tumor types that are not responsive to current cancer immunotherapies because there are few T-cells in the tumor. In addition, combination immunotherapy of RG7802 with Tecentriq is expected to yield a potent antitumor effect in various CEA-positive cancers by inducing further T-cell activation. Chugai started a phase I clinical study of RG7802 for the treatment of solid tumors in Japan in January 2018.

**RG7828 Development project**
Anti-CD20/CD3 bispecific antibody
(Generic name: mosunetuzumab)

RG7828 is a bispecific antibody in-licensed from Roche. Similar to RG7802, it is expected to activate T cells and attack tumor cells by cross-linking CD3 on T cells to CD20 on B cells. Chugai started a phase I clinical study for the treatment of hematologic tumors in Japan in March 2018.

**RG7461 Development project**
Anti-FAP humanized antibody-engineered IL-2 variant fusion protein

RG7461 is an anti-FAP humanized antibody-engineered IL-2 variant fusion protein in-licensed from Roche. Targeting an interleukin-2 (IL-2) variant in tumor stroma that overexpress fibroblast activation protein (FAP), it is expected to demonstrate efficacy against tumor cells by inducing activation of immune effector cells in the tumor microenvironment. In October 2019, Chugai began a phase I clinical trial of RG7461 for solid tumors in Japan.

**RG6058 Development project**
Anti-TIGIT fully humanized monoclonal antibody
(Generic name: tiragolumab)

RG6058 is an anti-TIGIT monoclonal antibody in-licensed from Roche. TIGIT is an immune checkpoint expressed on the surface of NK cells and T cells that binds to poliovirus receptors (PVR) expressed on tumor cell surfaces. This binding is thought to allow the cancer cells to evade attack by immune cells. RG6058 restores and maintains the immune response of NK cells and T cells by blocking the binding of TIGIT to PVR, and is thus expected to demonstrate efficacy against cancer cells. In November 2019, Chugai began a phase I clinical trial of RG6058 for solid tumors in Japan.
Osteoporosis

Osteoporosis is a disease in which the bones become weak due to advanced age or other factors, increasing the risk of fractures. Osteoporosis patients may incur fractures through normal daily activities. Among these, compression fractures of the spine and femoral neck fractures can decrease quality of life by leaving patients bedridden and can also increase mortality risk. About 13 million people in Japan suffer from osteoporosis. However, the treatment rate stands at around only 20 percent of the estimated number of sufferers because there are usually no symptoms until a fracture occurs. The availability of superior new drugs that have higher efficacy, safety and convenience has brought promise for improvement in the quality of life of patients.

Treatment Methods

Osteoporosis drug therapies include active vitamin D3 derivatives, which improve bone metabolism, bisphosphonates, which are bone resorption inhibitors, an anti-RANKL antibody, selective estrogen receptor modulators (SERMs), human parathyroid hormone (PTH), which is a bone formation agent, anti-sclerostin antibodies, and calcitonin.

Regulatory Trends

National prevention and treatment guidelines for osteoporosis were revised in October 2006. Subsequently, advances have been made in basic and clinical research into osteoporosis; evaluation of fracture risk and criteria for the initiation of drug treatment have been reviewed; and osteoporosis caused by lifestyle-related diseases has been addressed. In the interim, Edirol and other medicines have been approved for insurance coverage. Revisions issued in December 2011 added preventive and diagnostic items in light of the importance of early prevention to broaden the overall scope of osteoporosis treatment. Since then, the 2012 revised Diagnostic Criteria for Primary Osteoporosis and Management and Treatment Guidelines of Steroid-induced Osteoporosis have been adopted. Bonviva IV Injection and other medicines have been launched and covered by insurance, and revised guidelines were issued in July 2015.

Recently, an osteoporosis liaison service (OLS) initiated by the Japan Osteoporosis Society was introduced for the purpose of preventing osteoporosis and inhibiting bone fractures by coordinating the efforts of various healthcare professionals, including doctors, nurses, pharmacists and physical therapists. Medical staff involved in liaison and possessing extensive knowledge related to osteoporosis are called osteoporosis managers. This education program has been ongoing since 2012, and more than 3,061 managers. This education program has been ongoing since 2012, and more than 3,061 osteoporosis managers were active as of April 2019.

Edirol

Active vitamin D3 derivative
(Generic name: eldecalcitol)
Launch in Japan: April 2011

Basic Information

Edirol, a vitamin D3 preparation born out of Chugai’s many years of research in vitamin D, is an agent that improves bone metabolism in addition to calcium metabolism. Chugai started sales of Edirol in April 2011 as the successor drug to Alfarol for the indication of osteoporosis. Under an agreement signed in May 2008, Edirol has been co-developed and is currently co-marketed with Taisho Pharmaceutical Co., Ltd. Clinical trials have confirmed that Edirol has a similar safety profile to alfalcacidol with a statistically significant greater effect in preventing fractures. In the 2015 osteoporosis prevention and treatment guidelines, Edirol received a Grade A recommendation, the only one for an active vitamin D3 derivative, for its effectiveness in increasing bone density and preventing vertebral fractures.

Review of 2019 Performance

Sales of Edirol increased ¥3.8 billion, or 11.6 percent, to ¥36.7 billion. It has become the most widely used active vitamin D3 preparation because of its superior efficacy in increasing bone mass and preventing fractures compared with existing products. Recognition and understanding of Edirol as a base treatment has broadened. As a result, its use in combination with other drugs is expanding, as are prescriptions, primarily for new cases.

In China, an application has been filed for approval of Edirol for osteoporosis.

Bonviva

Bisphosphonate anti-resorptive agent
(Generic name: ibandronate)
Launch in Japan: August 2013

Basic Information

Bonviva is a bisphosphonate in-licensed from Roche. Bonviva IV Injection was launched in August 2013. Under an agreement signed in September 2006, Bonviva is being co-developed and co-marketed with Taisho Pharmaceutical Co., Ltd. Bonviva IV Injection can be given as a rapid intravenous injection once a month, and thus may significantly reduce the burden on patients. It is also expected to benefit patients who have difficulty taking oral formulations or who tend to forget to take their medication. In addition, Bonviva Tablet, a once-monthly oral formulation, demonstrated non-inferiority to Bonviva IV Injection in a phase III clinical trial, and Chugai began sales in April 2016. By enabling drug selection according to patient lifestyle, monthly Bonviva IV Injection and Bonviva Tablet are expected to help improve patient adherence, convenience for healthcare providers and the rate of continuation of treatment.
Systemic juvenile idiopathic arthritis (sJIA) accounts for 30 to 40 percent of all JIA cases, but steroids, the main treatment for sJIA, can cause growth impairment and other adverse reactions. Consequently, the approval and launch of Actemra for sJIA in April 2008 provided a significant advance in therapy.

* Source: Evaluate Pharma

**Regulatory Trends**

In November 2018, MHLW released an update of the Report of the Rheumatism and Allergy Countermeasure Committee, which was previously issued in 2005 and 2011. To maximize long-term quality of life of RA patients through appropriate treatment that controls disease activity, and to provide comprehensive support in daily life at workplaces and schools, and for life events such as pregnancy and childbirth, the report calls for (1) enhancement of medical service systems; (2) improvement of the patient environment, including consultation opportunities and access to information, and (3) promotion of research and development and other activities. In Europe, revised treatment recommendations in 2013 added Actemra and Abatacept to the biologic drugs recommended in first-line therapy, which were previously limited to anti-TNF agents. In 2015, a proposed update of clinical practice guidelines was announced at the American College of Rheumatology, with biologics including Actemra added as first-line therapy along with anti-TNF agents. Moreover, the updated European League Against Rheumatism (EULAR) recommendations that were announced in June 2016 state the superiority of interleukin-6 (IL-6) inhibitor therapy over other biologics in cases where MTX and other therapies cannot be used.

**Castleman’s Disease**

Castleman’s disease is a lymphoproliferative disease characterized by symptoms such as systemic lymphadenopathy, fever and general fatigue, as well as various abnormal laboratory test values including anemia, hypergammaglobulinemia and hypoalbuminemia. It has been confirmed that these manifestations result from the excessive production of IL-6, one of the cytokines that causes inflammation. Castleman’s disease is very rare, affecting approximately 1,500 people in Japan.
Takayasu arteritis leads to inflammation of the aortic arch and its branch vessels. It affects women more than men, at a ratio of 9:1, and age of onset is between 20 and 50 years. It occurs most commonly in Asia, including Japan, and the Middle East. Initial symptoms are reduced head and cerebral blood flow related conditions, primarily dizziness, lightheadedness and headaches, as well as neck pain, chest pain and vascular pain along the limb arteries.

Giant cell arteritis is a granulomatous vasculitis occurring primarily in the aorta and aortic branches, mainly the temporal arteries. It also affects women more than men, at a ratio of 1.6:1, and the age of onset is 55 years or older. It occurs most commonly in Western countries and is rare in Japan. Common initial symptoms include headache, systemic conditions such as fever, and loss of vision.

**Adult Still’s Disease**

Adult Still’s disease is an autoimmune disease that typically presents with a high spiking fever, aching joints and a light-pink rash. Leukocytosis, increased C-reactive protein (CRP) levels, and elevated erythrocyte sedimentation rates are frequently observed in laboratory findings. Inflammation suppression with corticosteroids is the standard therapy, but until recently, no drug covered by the National Health Insurance was available for steroid-resistant patients.

**Actemra (MRA/RG1569)**

Humanized anti-human IL-6 receptor monoclonal antibody

(Generic name: tocilizumab)

Launch in Japan: June 2005

**Basic Information**

Actemra, created by Chugai and the first therapeutic antibody originating in Japan, blocks the activity of IL-6, a type of cytokine. It was launched in Japan in June 2005 as a treatment for Castleman’s disease. In April 2008, Chugai obtained approval in Japan for the additional indications of RA, polyarticular juvenile idiopathic arthritis (pJIA) and sJIA. In May 2013, Chugai launched an auto-injector for the Japanese RA market. As of December 2017, Actemra was marketed in Japan.

Actemra is marketed globally through Roche. In Europe, where the medicine is known as RoActemra, sales for the treatment of RA started in 2009. Chugai’s marketing subsidiary co-promotes RoActemra with Roche in the United Kingdom, France and Germany. In the United States, Actemra obtained approval in January 2010 for the treatment of adult patients with moderate to severe active RA who have had an inadequate response to one or more anti-TNF agents, and obtained approval in August 2010 as a first-line biologic treatment. In Taiwan and South Korea, where Chugai has marketing rights, Actemra obtained approval in July 2011 and April 2012, respectively. Following its launch in Japan, the subcutaneous formulation obtained approval in the United States in October 2013 and in Europe in April 2014, and has been launched in both markets. RoActemra was also approved for early RA in Europe in September 2014.

Furthermore, Actemra obtained approval for the additional indication of treatment of sJIA in the United States in April 2011 and in Europe in August 2011. Actemra also received breakthrough therapy designation from the U.S. FDA in 2016 for giant cell arteritis. In Japan, it became possible in June 2017 to reduce the dose interval of Actemra from two weeks to one week in patients with an inadequate response to use of the subcutaneous formulation for RA. Actemra obtained approval in Japan for the additional indications of Takayasu arteritis and giant cell arteritis in August 2017, and in the United States, in November 2018 an autoinjector obtained approval for an additional formulation for the treatment of RA, giant cell arteritis, sJIA and pJIA. Actemra also obtained approval in the United States in August 2017 and in Europe in August 2018 for the additional indication of chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome, and in Japan in March 2019 for the additional indication of cytokine release syndrome induced by tumor-specific T cell infusion therapy.

**Review of 2019 Performance**

Sales of Actemra in Japan increased ¥3.6 billion, or 9.4 percent, to ¥41.8 billion. The increase continued to be driven by the strong growth of the subcutaneous formulation after Chugai obtained approval for an additional dosage and administration with a shorter dose interval of the subcutaneous formulation for RA, and for the additional indications of Takayasu arteritis and giant cell arteritis. Sales of the subcutaneous formulation accounted for more than 60 percent of the total.

Sales of Actemra outside Japan (including exports to Roche) increased ¥7.7 billion, or 9.6 percent, to ¥88.3 billion. Roche’s global sales increased 6.0 percent year on year with 9.6 percent, to ¥88.3 billion. Roche’s global sales increased 6.0 percent year on year with 9.6 percent, to ¥88.3 billion.
Suvenyl
Agent for joint function improvement
(Generic name: sodium hyaluronate)
Launch in Japan: August 2000

Basic Information
Suvenyl is a drug that improves joint function through injection into the joint cavity, is a high-molecular weight sodium hyaluronate drug that alleviates knee osteoarthritis, shoulder periarthritis and knee joint pain caused by RA. With physical and chemical properties close to that of hyaluronic acid found in the body, Suvenyl has been recognized for its superior performance, including its anti-inflammatory and analgesic effects.

Renal Diseases

Renal Anemia

Complications of Renal Dysfunction
In dialysis patients and end-stage chronic kidney disease (CKD) patients, a key issue is treating the various complications of advanced renal dysfunction, such as renal anemia, secondary hyperparathyroidism, and abnormal calcium and phosphorus metabolism. Of these complications, renal anemia is one of the most frequent, occurring not only in renal disease patients undergoing dialysis but also in pre-dialysis CKD patients. Renal anemia is associated with reduced quality of life, and is also a factor in the progress of organ damage, including decreased cardiac function and renal function.


Erythropoiesis-Stimulating Agent (ESA)
Erythropoietin (EPO) is a hemopoietic factor produced mainly in the kidneys. It stimulates erythrocyte production by binding to EPO receptors on erythroid progenitor cells in bone marrow. An erythropoiesis-stimulating agent (ESA) is effective in treating renal anemia caused primarily by the decline in EPO production due to CKD, and is thought to help improve quality of life. ESAs are currently used by approximately 80 percent of dialysis patients as well as by some pre-dialysis CKD patients with renal anemia. ESAs are thus an essential drug for the treatment of renal anemia.

Flat-Sum Reimbursement System for ESAs
Since the 2006 revisions of medical fees, ESAs have been included in medical fee points for hemodialysis (artificial kidney). The integrated fee points are reviewed with each revision of medical fees, and were reduced in 2016, which has led to intensified price competition for ESAs in the dialysis market.

Mircera
Long-acting erythropoiesis-stimulating agent (Generic name: epoetin beta pegol)
Launch in Japan: July 2011

Basic Information
Mircera is a drug that raises the stability of erythropoietin beta in the bloodstream through pegylation. It is a new type of renal anemia treatment with the longest serum half-life among ESAs, enabling stable and sustained control of anemia. It stimulates erythropoiesis through a different interaction with the EPO receptor on burst-forming unit erythroid (BFU-E) cells in the bone marrow. Mircera was launched in Japan in July 2011 as a treatment for renal anemia. Outside Japan, Mircera obtained approval in Europe in 2007 and is currently sold in more than 100 countries, including the United States.

The serum half-life of Mircera is virtually the same for intravenous or subcutaneous administration, and the drug demonstrates efficacy in relieving the symptoms of anemia when administered at four-week intervals during the maintenance period. Consequently, it is expected to reduce the burden of hospital visits on the aging population of patients with pre-dialysis CKD and to contribute to better treatment adherence. Furthermore, as a dialysis-related treatment, Mircera is expected to reduce the burden on medical staff and improve medical safety by dramatically reducing administration frequency, and is one of the options for the treatment of renal anemia.

Review of 2019 Performance
Sales decreased ¥0.6 billion, or 7.7 percent, to ¥7.2 billion, due to the impact from NHI drug price revisions and competing products. In China, phase III clinical studies are under way for knee osteoarthritis and shoulder periarthritis.

Oxarol
Agent for secondary hyperparathyroidism
(Generic name: maxacalcitol)
Launch in Japan: September 2000

Basic Information
Synthesized by Chugai, Oxarol is the first intravenous active vitamin D3 derivative agent in Japan. It treats secondary hyperparathyroidism, a result of conditions such as impaired vitamin D activation associated with renal dysfunction, by acting directly on the parathyroid gland to control parathyroid hormone synthesis and secretion.
and by improving bone metabolic conditions. With its short serum half-life, Oxarol shows efficacy and enables treatment in patients who previously could not be treated adequately with oral vitamin D3 derivatives due to the onset of hypercalcemia.

Review of 2019 Performance
Sales of Oxarol decreased ¥0.4 billion, or 5.5 percent, to ¥6.9 billion due to the impact of the NHI drug price revision, despite slower uptake of a generic product.

**EOS789**
EOS789 is an oral drug created by Chugai with a molecular weight of over 500 g/mol. A phase I clinical trial of EOS789 for hyperphosphatemia has been completed.

---

**Neurology**

### Alzheimer’s Disease

Alzheimer’s disease (AD) is the most common form of dementia. Pathologically, it is a progressive neurodegenerative disease that causes neuron death in the brain and brain atrophy. It leads to a general and progressive loss of memory and other cognitive functions, which can interfere with daily life. While existing AD treatments have some effect in slowing the progression of dementia symptoms, they do not slow pathological progress and are unable to stop neuron death, and a treatment for the underlying cause does not yet exist. Consequently, unmet medical need is high, and there is strong demand for a more effective drug.

**RG1450**
Anti-amyloid-beta human monoclonal antibody (Generic name: gantenerumab)

RG1450 targets aggregate amyloid beta, with a high binding affinity to plaques in particular. It is expected to reduce cognitive deterioration by removing amyloid beta in the brain. Global phase III multinational studies of RG1450 for AD began in June and July 2018.

**RG6100**
Anti-tau humanized monoclonal antibody (Generic name: semorinemab)

RG6100 binds to tau proteins found in the extracellular space of the brain, and is expected to slow the deterioration of cognitive functions in AD by halting the propagation of tau via neurons. A phase I clinical trial for AD began in April 2019.

### Neuromyelitis Optica Spectrum Disorder

Neuromyelitis optica spectrum disorder (NMOSD) is a neurological autoimmune disorder characterized by severe optic neuritis and transverse myelitis. The disease affects 0.3 to 4.4 in 100,000 people, and there are about 4,000 patients in Japan. It is an incurable disease that typically appears around the age of 40 years and affects women more than men, at a ratio of 9:1. Symptoms include loss of vision (in some cases progressing to blindness) and impairment of motor function and sensation. In some cases, the disease results in death. However, NMOSD is an orphan disease with high unmet medical need. It is believed to occur mainly when aquaporin-4 (AQP4) in the central nervous system is attacked by autoantibodies called anti-AQP4 antibodies. Formerly, the diagnostic criteria of neuromyelitis optica (NMO) accompanied by optic neuritis and myelitis, and NMOSD accompanied by either optic neuritis or myelitis were proposed. Recently, however, it was proposed to reorganize and unify the definitions of both disorders under the term NMOSD. This term is now widely used to refer to a broader spectrum of disease.

**SA237**
Anti-IL-6 receptor humanized monoclonal antibody (Generic name: satralizumab)

SA237 is a next-generation therapeutic antibody that has shown success in blocking IL-6 receptors with a longer duration of action. Chugai created SA237 by applying its novel antibody engineering technology (Recycling Antibody engineering technology) that enables a single antibody molecule to block the target antigen repeatedly. As a result, a prolonged serum half-life has been demonstrated in clinical trials, which will make a longer dosing frequency possible. Because IL-6 promotes the production of the anti-AQP4 antibodies that are the primary cause of NMOSD, this drug is expected to improve (reduce recurrence of) the symptoms of these diseases as it inhibits the production of those antibodies by blocking the IL-6 signal. Two Chugai-sponsored global phase III studies in NMOSD patients achieved their primary endpoints. Chugai has licensed exclusive rights to Roche for the development and marketing of SA237 worldwide, with the exception of Japan and Taiwan. SA237 has been designated as an orphan drug in Japan, the United States and Europe, and was granted breakthrough therapy designation by the FDA in December 2018 for the treatment of NMOSD. Applications for approval of SA237 for of NMOSD were filed in the United States and Europe in August 2019 and in Japan in November 2019.

### Huntington’s Disease

Huntington’s disease is a hereditary, intractable, progressive neurodegenerative disease that causes nerve cells in the brain to break down. Characterized mainly by involuntary movements (most commonly chorea), neuropsychiatric symptoms and dementia, this disease profoundly affects the lives of affected individuals. As the disease progresses, people with Huntington’s disease may develop walking and swallowing difficulties, personality changes and loss of cognitive functions.

The prevalence of Huntington’s disease varies by ethnicity and geographical location. It is reported to affect 4 to 8 out of every 100,000 people in Western countries, but in Japan it is a rare disease, affecting 0.7 out of every 100,000 people, about 1/10 the rate in the United States and Europe. Existing drug therapies treat chorea and other involuntary movements, as well as neuropsychiatric symptoms, but a treatment for the underlying cause does not yet exist.

---
RG6042  Development project  
**Antisense oligonucleotide (ASO) targeting human huntington messenger ribonucleic acid (HTT mRNA)**  
(Generic name: tominersen)

RG6042 is an ASO targeting human HTT mRNA, which is believed to be the cause of Huntington’s disease. It has the potential to delay or slow disease progression in people with Huntington’s disease by binding specifically to HTT mRNA, after which synthesis of the HTT protein is inhibited. A global phase III study began in March 2019. RG6042 has received orphan drug designation as a treatment for Huntington’s disease in Japan, the United States and Europe, and was granted PRIIME designation by the European Medicines Agency in 2018.

### Spinal Muscular Atrophy

Spinal muscular atrophy (SMA) is a lower motor neuron disease characterized by amyotrophy and progressive muscle weakness caused by degeneration of anterior horn cells in the spinal cord. The estimated number of patients in Japan is reported to be around 1,000. The disease is caused by a defect in the SMN1 gene, and onset usually occurs in childhood. In severe cases it is fatal.

**RG7916  Development project**  
**SMN2 splicing modifier**  
(Generic name: risdiplam)

RG7916 is an SMN2 splicing modifier that increases generation of a protein derived from the SMN2 gene. This protein is nearly identical to the protein made from the SMN1 gene, which is not functional in SMA patients. RG7916 shows promise in improving neural and muscular function. Global phase II/III studies are under way, and RG7916 met its primary endpoint in the SUNFISH study in patients with Type 2 or 3 SMA and the FIREFISH study in patients with Type 1 SMA, respectively. RG7916 was granted PRIIME designation by the European Medicines Agency in December 2018, and received orphan drug designation in Japan in March 2019.

### Parkinson’s Disease

Parkinson’s disease is a progressive neurodegenerative disease characterized by aggregation of $\alpha$-synuclein in the central nervous system and peripheral nervous system. A wide range of motor symptoms (tremor, muscle rigidity, akinesia, impairment of postural reflexes, etc.) and non-motor symptoms (sleep disorders, autonomic dysfunction, cognitive and mental disorders, etc.) occur. The estimated number of patients in Japan is 200,000. A progressive disease seen mainly in people age 50 or older, it can lead to becoming bedridden as the condition worsens.

**RG7935  Development project**  
**Anti-$\alpha$-synuclein monoclonal antibody**  
(Generic name: prasinezumab)

RG7935 is a monoclonal antibody that targets $\alpha$-synuclein. It slows the expansion of nerve cell death by inhibiting the cell-to-cell propagation of aggregated forms of neurotoxic $\alpha$-synuclein, and is expected to reduce and delay progression of the disease. In a phase I clinical trial that began in 2018, RG7935 demonstrated good tolerability, and there were no significant racial differences in pharmacokinetics.

### Autism Spectrum Disorder

Autism spectrum disorder (ASD) is a lifelong neurodevelopmental disorder presenting impairments of social interaction and communication and repetitive behaviors (restricted interests), and is thought to be mainly caused by a genetic factor. ASD is estimated to affect about 1 percent of the population.

**RG7314  Development project**  
**Vasopressin 1a receptor antagonist**  
(Generic name: balovaptan)

RG7314 is expected to improve social interaction and communication in people with ASD by suppressing the activity of the vasopressin 1a receptor in the brain. A phase I clinical trial of RG7314 for ASD began in May 2019.

### Others

**GYM329/RG6237  Development project**  
**Anti-latent myostatin sweeping antibody**

GYM329, created by Chugai, is a next-generation antibody that applies Chugai’s proprietary antibody engineering technologies, including its recycling antibody and sweeping antibody technologies. Latent myostatin is an inactive form that is mainly secreted from muscle cells, and is activated by BMP-1 and other protein degrading enzymes. Activated myostatin inhibits muscle growth and hypertrophy, and by inhibiting myostatin, GYM329/RG6237 is expected to improve the various conditions associated with muscle atrophy and loss of muscular strength. Currently under development for neuromuscular disease, this antibody began a phase I clinical trial in October 2018. Chugai out-licensed GYM329 to Roche at an early stage before the start of clinical testing in order to accelerate global development by taking advantage of Roche’s experience and expertise.

**RG7906  Development project**

RG7906 is a small molecule drug in development for psychiatric disorders. A phase I clinical trial began in January 2019.
Hemophilia

Hemophilia is a disease that leads to bleeding in the joints, muscles and other areas in the body due to a congenital deficiency or abnormal function of blood coagulation factors. A low level or absence of blood coagulation factor VIII is known as hemophilia A, while a low level or absence of blood coagulation factor IX is referred to as hemophilia B. Treatment of hemophilia A is centered on replacement therapy to supplement factor VIII. However, since it involves intravenous injections two to three times a week, treatment is a significant burden, particularly on children. Moreover, patients must be monitored for the development of autoantibodies, called inhibitors, to the supplemented factor.

Patients with inhibitors are treated by means such as bypass therapy or immune tolerance therapy, but these therapies are limited in terms of convenience and the stability of their effects. A more useful treatment method is therefore needed.

Hemlibra (ACE910/RG6013)
Anti-coagulation factor IXα/X humanized bispecific monoclonal antibody
(Generic name: emicizumab)
Launched in Japan: May 2018

Hemlibra is a bispecific antibody that employs Chugai’s innovative antibody engineering technologies. Like factor VIII, which is low or missing in hemophilia A, Hemlibra simultaneously binds to factor IXa and factor X, stimulating the activation of factor X by activated factor IX and promoting normal blood coagulation for hemostasis. Unaffected by inhibitors, Hemlibra can prevent bleeding with subcutaneous injections once a week, once every two weeks, or once every four weeks, and is promising as a drug that can change the existing system of treatment. Another key feature is that Chugai’s proprietary technology ART-Ig is applied to Hemlibra, enabling industrial production of bispecific antibodies.

Chugai concluded an out-licensing agreement with Roche in July 2014 and in May 2017 entered into a license agreement with JW Pharmaceutical Corporation for the exclusive marketing rights in South Korea. The drug received breakthrough therapy designation from the U.S. FDA in September 2015 for its potential to prevent bleeding in hemophilia patients with inhibitors, and in April 2018 for its potential to prevent bleeding in patients without inhibitors. In the United States, Hemlibra received priority review designation in August 2017, and in November 2017 obtained approval for routine prophylaxis with once-weekly subcutaneous administration in adult and pediatric patients with hemophilia A with factor VIII inhibitors. Hemlibra was also granted accelerated assessment in Europe, and received regulatory approval from the European Commission in February 2018. In Japan, it obtained approval in March 2018 and was launched in May 2018. It also obtained approval in Taiwan in December 2018 and was launched there in November 2019.

Applications were filed in the United States, Europe and Japan in April 2018, and in Taiwan in January 2019, for routine prophylaxis of bleeding episodes, as well as for additional dosage and administration as a biweekly or four-weekly treatment, for people with hemophilia A without inhibitors. In the United States, Hemlibra was granted priority review status in June 2018, and in October 2018, it obtained approval for prophylactic treatment by subcutaneous administration once weekly, every two weeks, or every four weeks in adults or children with hemophilia A without inhibitors, as well as additional dosing options of every two weeks or every four weeks in adults and children with hemophilia A with inhibitors. Hemlibra also obtained approval in Japan in December 2018, and in the EU in March 2019.

Review of 2019 Performance
Sales of Hemlibra increased ¥22.2 billion, or 740 percent, year on year to ¥25.2 billion. Hemlibra has a different mode of action than factor VIII and a long half-life, supporting a steady increase in uptake for patients without inhibitors. In particular, switches to Hemlibra took place early on in pediatric patients with difficult venous access, surpassing expectations.

NXT007 Development project
Anti-coagulation factor IXα/X bispecific antibody

NXT007, created by Chugai, is a bispecific antibody that stimulates blood coagulation using the same mode of action as Hemlibra. One difference from Hemlibra is the application of Chugai’s antibody engineering technologies FAST-Ig, which enhances large-scale production of the bispecific antibody and ACT-Fc, which is expected to improve antibody pharmacokinetics. NXT007 is expected to achieve the levels of hemostasis found in healthy adults and children, and is being developed to improve convenience, including the administration device. A phase I/II clinical trial for hemophilia A began in August 2019.

Influenza

Influenza is an acute infectious disease characterized by the rapid onset of high fever (38 degrees centigrade or higher) and severe systemic symptoms. It is highly infectious, and epidemics can develop quickly. In some cases, secondary infections can lead to very serious illness and death. Influenza is classified into types A, B and C based on differences in the antigenicity of the underlying virus. Types A and B can infect humans and cause major outbreaks.

Tamiflu
Anti-influenza agent
(Generic name: oseltamivir)
Launch in Japan: February 2001

Basic Information
Tamiflu is an oral anti-influenza agent that is effective against both type A and type B infections. It inhibits viral replication by blocking the action of neuraminidase, an enzyme essential for the multiplication of the influenza virus. Launched in capsule form in February 2001 and dry syrup form in July 2002, dosages are available for patients one year of age and older. From March 2007, restrictions on the use of Tamiflu in teenage patients with seasonal influenza were in force in Japan. The measure was introduced as a safety precaution following several reports of abnormal behavior in influenza patients who had taken Tamiflu. In May 2018, the Subcommittee on Drug Safety of the Ministry of Health, Labour and Welfare confirmed that abnormal behavior occurs
 regardless of whether anti-influenza drugs have been given, and in July 2018, the same subcommittee decided that the restrictions should be removed. Accordingly, the package insert was revised and restrictions on the use of Tamiflu in teenage patients were removed in August 2018.

The shelf life of Tamiflu capsules was extended to 10 years from seven years for capsules manufactured after July 2013, and the shelf life of Tamiflu dry syrup was extended to 10 years starting with the portion shipped in 2015. In March 2017, Chugai obtained approval for additional dosage and administration of Tamiflu dry syrup for neonates and infants younger than 12 months.

Review of 2019 Performance
Ordinary sales of Tamiflu decreased ¥2.7 billion, or 26.7 percent, to ¥7.4 billion, while sales for government stockpiles were ¥3.2 billion. The decrease in sales in 2019 reflected the market entry of (baloxavir marboxil), which has a novel mode of action, and a generic version of Tamiflu. The market share of Tamiflu recovered in December 2019 because relevant scientific societies recommended restricting the use of (baloxavir marboxil) in children under 12 years of age due to concerns about drug-resistant viruses.

Others

**CellCept**
Immunosuppressant
(Generic name: mycophenolate mofetil)
Launch in Japan: November 1999

Sales of CellCept increased ¥0.3 billion, or 3.3 percent, to ¥9.3 billion. CellCept is used to treat refractory rejection after kidney transplants and to prevent rejection after kidney, heart, liver, lung and pancreas transplants. The need for transplantation medication has been rising in Japan, driven by advances in transplantation therapy. In May 2016, CellCept received approval for the indication of lupus nephritis, a refractory disease associated with the autoimmune disease systemic lupus erythematosus.

**Atopic Dermatitis**
A type of allergic disorder, atopic dermatitis is a chronic skin disease characterized by an itchy rash that alternately improves and worsens. Scratching the affected area exacerbates the skin symptoms and makes the itching worse, leading to an itch-scratch cycle. The basic treatment is drug therapy using topical steroid preparations and/or immunosuppressants to control the inflammation and a skin care regimen to prevent the inflammation from recurring.

**Prurigo Nodularis**
Prurigo nodularis is a chronic skin disorder that causes thick papules or nodules accompanied by intensive itching. Patients with prurigo nodularis worry that the severe itching will interfere with their daily lives. The cause of prurigo nodularis is not yet fully understood, and control of the symptoms is difficult, and thus an effective treatment is needed.

**CIM331**
Anti-IL-31 receptor A humanized monoclonal antibody
(Generic name: nemolizumab)

Nemolizumab (CIM331) is an anti-IL-31 receptor A humanized monoclonal antibody originating from Chugai. The drug is expected to improve itching and skin inflammation in atopic dermatitis by blocking IL-31, a proinflammatory cytokine, from binding to its receptor.

In July 2016, Chugai entered into a global license agreement granting Galderma S.A. of Switzerland exclusive rights for the development and marketing of nemolizumab worldwide, with the exception of Japan and Taiwan. In September 2016, Chugai entered into a license agreement granting Maruho Co., Ltd. the rights for the development and marketing of nemolizumab in the skin disease area for the Japanese market. In the development of CIM331 for atopic dermatitis, in 2019 Maruho achieved the primary endpoints in a phase III clinical study and Galderma started a global phase III study. In addition, CIM331 was granted breakthrough therapy designation by the FDA for pruritus associated with prurigo nodularis. Galderma plans to start a phase III clinical study for prurigo nodularis in 2020.

**Paroxysmal Nocturnal Hemoglobinuria**
Paroxysmal nocturnal hemoglobinuria (PNH) is a disorder that leads to complications such as thrombosis and CKD, in addition to anemia and dark brown urine caused by hemolysis as well as infections and bleeding tendency associated with a decrease in white blood cells and platelets. It is an acquired genetic disorder that affects hematopoietic stem cells, causing the creation of red blood cells that have no complement resistance, and hemolysis occurs when complements are activated in vivo. An estimated 430 patients suffer from PNH in Japan (according to a fiscal 1998 epidemiological survey by the Ministry of Health, Labour and Welfare), and the disease reportedly affects approximately 5,000 people globally. Although this number is small, PNH is a progressive disease with a high risk of mortality.

**SKY59/RG6107**
Anti-C5 recycling antibody
(Generic name: crovalimab)

SKY59 is a recycling antibody discovered by Chugai that inhibits the C5 complement component.

The onset of a number of diseases is reported to be caused by complement activation. SKY59 is expected to inhibit cleavage of C5 to C5a and C5b, thus suppressing complement activation and improving disease conditions. In PNH, SKY59 may have a suppressive effect on hemolysis by preventing the destruction of red blood cells. Application of multiple Chugai proprietary antibody engineering technologies resulted in a prolonged half-life (in preclinical trials), and the antibody is being developed as a subcutaneous self-injection. Due to the severity of the disease, regular administration is necessary, but making self-injection possible is expected to lessen the burden on patients by reducing the frequency of hospital visits. Chugai is co-developing SKY59 with Roche, and a global phase II/III study began in November 2016. In September 2017, SKY59 received orphan drug designation in the United States for PNH.
**wAMD/DME**

Wet age-related macular degeneration (wAMD) is a disease in which abnormal blood vessel growth (choroidal neovascularization) caused by age-related accumulation of waste products extends into the space under the retinal pigment epithelium (RPE) or between the retina and the RPE, leading to retinal tissue damage. If the choroidal neovascularization and the associated effusion progress into the fovea centralis, which governs vision, it may lead to deterioration of visual acuity along with the symptoms of image distortion, vision loss and central scotoma. Left untreated, wAMD may lead to irreversible visual impairment.

Diabetic macular edema (DME) is a retinal disease associated with diabetic retinopathy. In diabetes, consistently high blood sugar causes blockage of retinal capillaries, ischemic change, and edema induced by vascular hyperpermeability. Blurred vision occurs when swelling extends to the central part of the macula, which governs vision. Left untreated, DME may lead to irreversible visual impairment.

**RG7716 Development project**

Anti-VEGF/Ang-2 bispecific antibody (Generic name: faricimab)

RG7716, which Chugai in-licensed from Roche, is the first bispecific antibody for ophthalmology diseases. It selectively binds to vascular endothelial growth factor A (VEGF-A), a key mediator of angiogenesis and vascular permeability, and angiopoietin-2 (Ang-2, an antagonist of Ang-1, which contributes to the stability of mature vessels), a destabilizer of chorioretinal vessels and inducer of vascular permeability. By simultaneously neutralizing intraocular VEGF-A and Ang-2 in wAMD and DME patients, RG7716 is expected to demonstrate better treatment outcomes and a more sustained effect than the anti-VEGF drugs that are the current standard of care. Global phase III studies for the potential treatment of DME and wAMD began in September 2018 and February 2019, respectively.

**Endometriosis**

Affecting one out of 10 women in their twenties to forties, endometriosis is the repeated proliferation and shedding of endometrial tissue outside the uterus, accompanied by dysmenorrhea and chronic lower abdominal pain, and is a cause of infertility. The disease can interfere with daily life, including absences from work or school, as sufferers find it difficult to do more than lie still when symptoms are severe. The only existing medications are hormonal agents. Moreover, if the pain cannot be controlled by drugs, the only treatment is surgical removal, and many patients experience a recurrence several years after surgery, making this a disease with a high level of unmet medical need.

**AMY109 Development project**

AMY109 is the third therapeutic antibody to apply the recycling antibody engineering technology created by Chugai. Its approach differs from hormone therapy, which is the standard treatment for endometriosis, and its anti-inflammatory action is expected to provide new value to patients. A phase I clinical trial started in February 2018.

**Type 2 Diabetes**

Type 2 diabetes is an illness in which genetic predisposition and lifestyle cause impaired insulin secretion and resistance to insulin action, resulting in high plasma glucose concentration. There are no symptoms in the early stages, but if the condition is left untreated, the risk of cardiovascular diseases such as stroke and myocardial infarction increases. The disease can also cause complications such as retinopathy, nephropathy and neuropathy, which lead to blindness, dialysis and leg amputation, respectively, significantly reducing quality of life. According to the International Diabetes Federation, the number of people with diabetes worldwide, including prediabetes, is 463 million in 2019, and is projected to increase to 700 million in 2045. Treatment of this condition is thus a worldwide issue.

**OWL833 Development project**

OWL833 is an oral non-peptidic GLP-1 receptor agonist discovered by Chugai. GLP-1 agonists have potent hypoglycemic action and induce weight loss, but convenience for patients has been an issue because they are conventionally administered in a subcutaneous injection. Because OWL833 is orally bioavailable, it is easier for patients to take, and is thus expected to contribute to the treatment of diabetes, including through improvement of drug adherence. In September 2018, Chugai licensed the worldwide development and commercialization rights for OWL833 to Eli Lilly and Company. A phase I clinical study by Eli Lilly is under way.